<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01087021</url>
  </required_header>
  <id_info>
    <org_study_id>TES10884</org_study_id>
    <secondary_id>2009-016864-35</secondary_id>
    <secondary_id>U1111-1116-5677</secondary_id>
    <nct_id>NCT01087021</nct_id>
  </id_info>
  <brief_title>Effect of Cabazitaxel on the QTc Interval in Cancer Patients</brief_title>
  <acronym>QT-Cab</acronym>
  <official_title>QT-Cab: An Open-Label Study to Investigate the Effect of Cabazitaxel on the QTc Interval in Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

        -  To assess the potential effect on QTcF interval (QTc Fridericia) of cabazitaxel in
           cancer patients

      Secondary Objectives:

        -  To assess the effects of cabazitaxel on heart rate (HR), QT, QTcB (Bazett's correction),
           and QTcN (population specific correction) intervals

        -  To assess the clinical safety of cabazitaxel

        -  To assess cabazitaxel plasma concentrations at Cycle 1 at early timepoints (during
           infusion and up to 5h post end of infusion)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main period of the study consists of a maximum of 21-day screening phase, then first 2
      treatment cycles with cabazitaxel. End of main period will be Cycle 3 or 30 days after last
      dose if patient discontinues study after 1 or 2 treatment cycles. The duration for a patient
      for the main period of the study will be about 9 to 10 weeks (screening, 2 cycles).

      After Cycle 2, patients will have the option to continue to receive cabazitaxel and should be
      followed for safety reporting until 30 days after the last dose of cabazitaxel.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in QT interval corrected calculation by Fridericia method</measure>
    <time_frame>Cycle 1, Day 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Heart rate, QT, QTcB (QT interval corrected calculation by Bazett method) and QTcN (QT interval with a population-specific correction formulae) intervals</measure>
    <time_frame>Cycle 1, Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other ECG parameters : PR, QRS intervals and ECG morphology</measure>
    <time_frame>Cycle 1, Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical safety based on adverse events, serious adverse event, laboratory assessments according to the National Cancer Institute- Common Terminology Criteria for Adverse Events v4.0 grade scaling</measure>
    <time_frame>up to treatment discontinuation + 30 days over a maximum study period of 20 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cabazitaxel plasma concentrations, Cmax and partial AUC -</measure>
    <time_frame>Cycle 1, Day 1</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Neoplasms, Malignant</condition>
  <arm_group>
    <arm_group_label>cabazitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>At every cycle (every 3 weeks), on Day 1, patients will receive cabazitaxel, administered by intravenous (IV) infusion over 1 hour, at 25 mg/m2.
An IV premedication regimen composed of up to 4 treatments (antihistamine, corticosteroids, H2 antagonist other than cimetidine at all cycles, plus palonosetron at cycle 1) will be administered before cabazitaxel infusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cabazitaxel (XRP6258)</intervention_name>
    <description>Pharmaceutical form:solution for infusion
Route of administration: intravenous</description>
    <arm_group_label>cabazitaxel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Histologically or cytologically confirmed solid malignancy that is metastatic or
             unresectable, and for which standard curative measures do not exist, and a treatment
             with a novel taxane agent is considered.

        Exclusion criteria:

          -  Conditions with screening ECG repolarization difficult to interpret, or showing
             significant abnormalities. This includes, but is not limited to: high degree AV block,
             pace-maker, atrial fibrillation or flutter

          -  QTcF &gt;480 msec on screening Electrocardiogram (ECG)

          -  Significant hypokalemia at screening (serum potassium &lt;3.5 mMol/L)

          -  Significant hypomagnesemia at screening (serum magnesium &lt;0.7 mMol/L) (Note: Patient
             may be enrolled after correction of these laboratory abnormalities)

          -  Patient receives (and cannot discontinue), or is scheduled to receive a QT-prolonging
             drug

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 840006</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 840002</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 840005</name>
      <address>
        <city>Decatur</city>
        <state>Illinois</state>
        <zip>62526</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 840008</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 840010</name>
      <address>
        <city>Paducah</city>
        <state>Kentucky</state>
        <zip>42002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 840007</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 840009</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 840003</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 056002</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 056001</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 208002</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 208001</name>
      <address>
        <city>København Ø</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 528001</name>
      <address>
        <city>Maastricht</city>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 752002</name>
      <address>
        <city>Lund</city>
        <zip>221 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 752001</name>
      <address>
        <city>Uppsala</city>
        <zip>751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>Netherlands</country>
    <country>Sweden</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 12, 2010</study_first_submitted>
  <study_first_submitted_qc>March 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2010</study_first_posted>
  <last_update_submitted>December 15, 2011</last_update_submitted>
  <last_update_submitted_qc>December 15, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

